Peter Richardson, MD, Executive Vice President and Chief Scientific Officer of Mallinckrodt Pharmaceuticals, discusses recent data regarding Terlivaz (terlipressin) for hepatorenal syndrome (HRS).
HRS is a form of renal failure that occurs in patients with advanced chronic liver disease. It is characterized by intense renal vasoconstriction caused by interactions between systemic and portal hemodynamics. This results in activation of vasoconstrictors and suppression of vasodilators in the renal circulation.
Terlipressin is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for improvement of kidney function in adults with HRS. Data from a pooled analysis of the CONFIRM, REVERSE, and OT-0401 phase 3 studies was presented at the 2024 American Association for the Study of Liver Diseases (AASLD) meeting.
HRS reversal among patients was assessed on day four after receiving 12 doses of terlipressin. From the analysis, it was observed that HRS reversal rates were 33.6% in the terlipressin group versus 16.8% in the placebo group. Additionally, 94.9% of patients achieving HRS reversal received more than 12 doses. Most patients achieving HRS reversal by the end of treatment required the medication beyond day four.
For more information, click here.
To learn more about rare hematologic disorders, visit https://checkrare.com/diseases/hematologic-disorders/